文献速递神经肿瘤

TERT启动子突变与脑膜瘤不良预后及细胞永生化相关

TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
PubMed 文献 · Neuro Oncol · 2018-01-01

该研究分析110例脑膜瘤患者共128份组织样本,直接测序检测TERT启动子C228T和C250T突变,并评估端粒酶活性、TERT mRNA表达及端粒长度。TERT启动子突变见于5.5%样本,与端粒酶活性和TERT mRNA显著上调相关。突变患者总生存显著缩短(53.8 vs 115.6个月,P=0.0006),且突变而非端粒酶活性或TERT mRNA表达预测体外细胞无限生长。

要点

  • 5.5%脑膜瘤样本存在TERT启动子突变C228T或C250T。
  • 突变者总生存显著缩短(53.8 vs 115.6个月,P=0.0006)。
  • TERT启动子突变预测体外细胞无限生长,突变细胞对YK-4-279高敏。

核心结论

  • TERT启动子突变驱动脑膜瘤侵袭性,导致患者生存缩短,但也可能为进展性疾病开辟新的治疗选择。

研究设计与样本

  • 分析110例世界卫生组织I-III级脑膜瘤患者的128份组织样本,直接测序检测TERT启动子C228T和C250T突变。
  • 128份样本中121份进行体外细胞增殖可行性测试。
  • 采用端粒重复扩增方案测定端粒酶活性,逆转录PCR检测TERT mRNA表达,定量PCR检测端粒长度。

主要发现

  • TERT启动子突变见于5.5%的分析样本,与端粒酶活性和TERT mRNA表达显著上调相关(两者P<0.0001)。
  • TERT启动子野生型与突变亚组间端粒长度无显著差异。
  • TERT启动子突变患者总生存显著缩短(53.8 vs 115.6个月,P=0.0006)。
  • TERT启动子突变而非端粒酶活性或TERT mRNA表达预测体外细胞无限生长。
  • TERT启动子突变脑膜瘤细胞对E-twenty-six(ETS)转录因子抑制剂YK-4-279高敏,诱导TERT启动子活性明显下调。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Meningiomas are mostly benign tumors tending to progress to higher-grade lesions. Mutations in the telomerase reverse transcriptase (TERT) gene promoter are comparably rare in meningioma, but were recently suggested to predict risk of recurrence and progression. Here we have analyzed a cohort of World Health Organization grades I-III meningiomas regarding the impact of TERT promoter mutations on patient prognosis and in vitro cell propagation feasibility. METHODS: From 110 meningioma patients, 128 tissue samples were analyzed for the TERT promoter mutations C228T and C250T by direct sequencing. Of the 128 samples, 121 were tested for cell propagation in vitro. Telomerase activity, TERT mRNA expression, and telomere lengths were investigated by telomeric repeat amplification protocol assay, reverse transcription PCR, and quantitative PCR, respectively. Impact of the E-twenty-six (ETS) transcription factor inhibitor YK-4-279 on cell viability and TERT promoter activity was analyzed. RESULTS: TERT promoter mutations were found in 5.5% of all samples analyzed and were associated with a significantly upregulated telomerase activity and TERT mRNA expression (P < 0.0001 both). Regarding telomere lengths, no significant difference between the TERT promoter wild-type and mutated subgroups was detected. Patients with TERT promoter mutated tumors exhibited significantly shorter overall survival (P = 0.0006; 53.8 vs 115.6 mo). The presence of TERT promoter mutations but not telomerase activity or TERT mRNA expression predicted indefinite cell growth in vitro. TERT promoter mutated meningioma cells were hypersensitive against the ETS transcription factor inhibitor YK-4-279, inducing a distinct downregulation of TERT promoter activity. CONCLUSION: TERT promoter mutations drive meningioma aggressiveness, resulting in reduced patient survival, but might also open novel therapeutic options for progressive disease.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Spiegl-Kreinecker S, Lötsch D, Neumayer K, et al. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro Oncol. 2018. PMID: 30010853. doi:10.1093/neuonc/noy104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。